scholarly journals Dasatinib-Induced Pulmonary Arterial Hypertension: A Case Report

2021 ◽  
Vol Volume 12 ◽  
pp. 33-39
Author(s):  
Ru Liu ◽  
Yinjiang Tang ◽  
Ting Fu ◽  
Jianli Zhou ◽  
Lijiao Ma ◽  
...  
Keyword(s):  
Case Report ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arterial

scholarly journals Pregnancy and pulmonary arterial hypertension: a case report

2021 ◽  
pp. 100135
Author(s):  
Ana Dias ◽  
Ana Mineiro ◽  
Luísa Pinto ◽  
Filipa Lança ◽  
Rui Plácido ◽  
...  
Keyword(s):  
Case Report ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arterial

Bosentan therapy for pulmonary arterial hypertension: a case report of a 16-month-old boy

2007 ◽  
Vol 23 (sup2) ◽  
pp. S103-S107
Author(s):  
Y. Dulac ◽  
R. Bassil ◽  
V. Gressin ◽  
S. Bonnet ◽  
E. Costello ◽  
...  
Keyword(s):  
Case Report ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arterial

Undiagnosed Pulmonary Arterial Hypertension at 33 Weeks’ Gestation: A Case Report

2010 ◽  
Vol 30 (2) ◽  
pp. 45-52
Author(s):  
Maureen A. Seckel ◽  
Carol Gray ◽  
Megan B. Farraj ◽  
Gerald O’Brien
Keyword(s):  
Case Report ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arterial

scholarly journals Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension: Serial Case Report

2021 ◽  
Vol 7 (2) ◽  
pp. 5
Author(s):  
Yunia Duana ◽  
Lucia Kris Dinarti ◽  
Dyah Wulan Anggrahini ◽  
Anggoro Budi Hartopo ◽  
Bambang Irawan
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pulmonary Hypertension ◽  
Case Report ◽  
Pulmonary Arterial Hypertension ◽  
Connective Tissue ◽  
Arterial Hypertension ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Initial Manifestation ◽  
Pulmonary Arterial

One of the causes of pulmonary arterial hypertension (PAH) is connective tissue disease, including systemic lupus erythematosus (SLE). The prevalence of PAH in patients with SLE according to cohort studies varies widely between 0.5% and 43%. In some cases, PAH is the initial manifestation leading to the diagnosis of SLE. However, PAH can develop as a complication in patients who are initially diagnosed with SLE. We report two cases with a different approach to the diagnosis of pulmonary hypertension in SLE patients. These cases emphasize the importance of investigating examination results according to the guidelines to establish the diagnosis of PAH in SLE.

scholarly journals A Hemodynamic Conundrum: A Case Report of a Patient with Concurrent Pulmonary Arterial Hypertension and Hypertrophic Obstructive Cardiomyopathy

2021 ◽  
Author(s):  
Ahmed Hassanin ◽  
Wojciech Rzechorzek ◽  
Srihari S Naidu ◽  
Gregg M Lanier
Keyword(s):  
Case Report ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Multidisciplinary Treatment ◽  
Hypertrophic Obstructive Cardiomyopathy ◽  
Left Ventricular ◽  
Alcohol Septal Ablation ◽  
Modest Improvement ◽  
First Case ◽  
Pulmonary Arterial

Abstract Background The co-existence of hypertrophic obstructive cardiomyopathy (HOCM) and pulmonary arterial hypertension (PAH) is extremely rare and poses a management conundrum. This is the first case report in the published literature to describe the diagnosis and management of a patient with both conditions. Case Summary A 49-year-old female with a history of HOCM and recently diagnosed scleroderma presented to the clinic with progressive dyspnoea. Transthoracic echocardiogram demonstrated left ventricular outflow tract (LVOT) obstruction at rest, and elevated pulmonary artery (PA) pressure. Cardiac catheterization (CC) demonstrated a LVOT gradient of 150 mmHg, PA pressure of 88/32 mmHg, pulmonary capillary wedge pressure (PCWP) 12 mmHg, pulmonary vascular resistance 14.8 Wu, and a cardiac index of 1.6 l/min/m2. The differential diagnosis for the dyspnoea included combined pre- and post-capillary pulmonary hypertension (PH) from longstanding HOCM vs. scleroderma associated PAH. Tadalafil was added to the patient’s medical regimen of metoprolol but it was stopped because the patient developed pulmonary oedema. Alcohol septal ablation was undertaken with improvement in the LVOT gradient, but only a modest improvement in her dyspnoea. Repeat CC demonstrated worsening PAH. Vasodilatory testing with nitric oxide led to an improvement in the PA pressure with minimal increase of the PCWP. Hence, she was started on treprostinil and macitentan, with significant improvement in her dyspnoea on Follow-up. Conclusion In patients with concurrent HOCM and advanced PAH, a multidisciplinary treatment approach is needed to rapidly and safely optimize the background of HOCM in order to permit the use of PAH specific medications.

Sign in / Sign up

Export Citation Format

Share Document